Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 12Lung Neoplasms 9Carcinoma, Hepatocellular 9Small Cell Lung Carcinoma 8Breast Neoplasms 6Urinary Bladder Neoplasms 5Triple Negative Breast Neoplasms 5Neoplasms 5Neoplasm Metastasis 5Melanoma 5Glioblastoma 5Carcinoma, Transitional Cell 5Ovarian Neoplasms 4Advanced Solid Tumor 4Stomach Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Sarcoma 3Prostatic Neoplasms 3Pancreatic Neoplasms 3Lymphoma, Non-Hodgkin 3Lymphoma, Follicular 3Liver Neoplasms 3Esophageal Neoplasms 3Carcinoma, Renal Cell 3Carcinoma, Neuroendocrine 3Solid Cancer 2Small Cell Lung Cancer Extensive Stage 2Recurrence 2Neuroendocrine Tumors 2Lymphoma, Large B-Cell, Diffuse 2

Interventions

lutetium Lu 177 dotatate 1atezolizumab 1Paclitaxel 1Etoposide 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Extensive Stage Small Cell Lung Cancer × atezolizumab × Clear all
NCT05142696 2026-05-29

A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab

Novartis

Phase 1/2 Active not recruiting
24 enrolled
Thoracic

Extensive Stage Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡